Keywords: Abbott,, PanGenetics, Licensing, Chronic pain, NGF
Abbott to acquire PanGenetics’ novel investigational biologic for chronic pain for up to $190 million
Article | 13 November 2009
US health care major Abbott says it has signed a definitive agreement to acquire the global rights to Dutch firm PanGenetics BV's early-stage PG110 fully-humanized antibody to Nerve Growth Factor (NGF), aiming to expand the company's pain care portfolio and leveraging its expertise in biologics.
The agreement includes an upfront $170 million plus additional milestone payments, for a total of up to $190 million. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
